Home » Newsletters » BioWorld Science

BioWorld Science

May 31, 2019

View Archived Issues

Clinical testing approved for the third-generation EGFR inhibitor XZP-5809

Gene minimizes mitotic chromosomal aberrations

FDA clears IND for phase I trial of BTX-A51 for AML and MDS

Results from a phase IIa study of reldesemtiv in patients with COPD

First-in-human results presented for adjuvant DC vaccine in patients with high-risk prostate cancer

Preliminary results of precision medicine-directed umbrella study of CCT301-38 and CCT301-59

First patient enrolled in phase III FALCON trial of bardoxolone for the treatment of AKPKD

Promising phase II efficacy data presented for NRX-101

CD206 plays a prognostic role in patients with DM/ILD

TP-0903 advances into phase Ib expansion stage in patients with advanced solid tumors

Inflazome patents new NLRP3 inflammasome inhibitors

Takeda identifies hSTING agonists

CSIR synthesizes new TLR9 antagonists

Shanghai ECUST Biomedicine patents tubulin polymerization inhibitors

Beijing Jialin Pharmaceutical discovers SMARCA2-targeting drugs for cancer

Patient recruitment ongoing in phase I study of BOS-475

Nonclinical toxicology studies support long-term administration of oral ibrexafungerp

First-in-human data for M-2000 in patients with early-stage breast cancer

Shionogi & Co. patents new antibacterial compounds

GT Biopharma provides clinical update for two phase I/II studies of GTB-1550

IVI and MCRI to coordinate global push to develop vaccine against Strep A

First study to test osilodrostat in children and adolescents with Cushing's disease

First patient dosed in phase I study of ALN-AGT

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for March 12, 2026.
Cas and effect: Merck’s phase III ripples HIF-2α space
BioWorld
Oddsmakers wasted no time figuring the market chances after Merck & Co. Inc. rolled out data from the phase III Litespark-011 study testing its oral...
Brain’s hidden tau-clearing pathway uncovered
BioWorld Science
Researchers at INSERM and collaborators have identified hypothalamic tanycytes as mediators of tau clearance and shown that their structural and genetic...
News in brief
BioWorld Asia
BioWorld Asia briefs for March 10, 2026
MSD synthesizes α-synuclein PET agents
BioWorld Science
Merck Sharp & Dohme LLC (MSD) has prepared and tested new positron emission tomography (PET) agents for binding and imaging α-synuclein (SNCA) for the diagnosis...